Local Manufacturing Capability in Gene Therapy

With its robust mammalian cell-based biopharmaceutical manufacturing infrastructure and expertise, Yerlika has now extended its capabilities to offer CDMO (Contract Development and Manufacturing Organization) services in viral vector-based gene therapies.

For gene therapies that play a pioneering role in cancer treatment, we provide our development partners with end-to-end support through:
💉 Customized manufacturing solutions,
⚙️ Process optimization, and
📈 Scalable production capabilities
all delivered in compliance with the highest quality standards.

This capability enables the rapid and regulatory-aligned development of next-generation immunotherapies that reprogram the immune system to fight cancer more effectively.

📌 In this context, we have successfully completed three validation batches of the active substance for Türkiye’s first domestically discovered gene therapy candidate, developed through academic research, at our Çerkezköy facility.

🔬 While quality analyses and stability studies are ongoing, we are actively preparing for the transition to the preclinical phase.

This achievement, in a field where only a limited number of advanced technology companies operate globally, reflects the engineering discipline and manufacturing excellence of our young and highly skilled team.

🙌 We extend our sincere gratitude to all our team members and partners who contributed to this success.

At Yerlika, we remain fully committed to expanding our biotechnological manufacturing capabilities and positioning our country as a competitive player in the field of innovative therapeutic technologies